ASCO 2022 | B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6

Gerald Steven Falchook, MD, Sarah Cannon Research Institute at HealthONE, Denver, CO, provides an overview of the rationale and study design of a Phase I dose-escalation trial of BI 765049 with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors expressing B7-H6. BI 765049 is a novel IgG-like bispecific T-cell engager designed to bind simultaneously to B7-H6 on tumor cells and CD3 on T cells, resulting in cytolytic synapse formation and tumor lysis. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.